Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer is a research paper published in Clinical Lung Cancer (2022). On theSindex it has a DataRank of 0.489. It has been cited 14 times, with 9 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.406
From this paper's citation signal
Citation Network Contribution
0.0827
From 6 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 9 citers.
National Cancer Institute
Grant: P30 CA008748
NCI NIH HHS
Grant: R50 CA275877
Merck Sharp and Dohme
National Institutes of Health
Merck & Co Inc
FWCI
1.02
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords